InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com – Defense World

Investment analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR Get Rating) in a report issued on Tuesday. The firm set a sell rating on the stock.

Shares of InspireMD stock opened at $2.05 on Tuesday. The stocks 50-day simple moving average is $1.98 and its 200-day simple moving average is $2.41. InspireMD has a 52 week low of $1.68 and a 52 week high of $5.06. The company has a market capitalization of $17.07 million, a price-to-earnings ratio of -0.98 and a beta of 1.27.

InspireMD (NYSE:NSPR Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) EPS for the quarter. The business had revenue of $1.18 million during the quarter. InspireMD had a negative net margin of 345.80% and a negative return on equity of 45.79%.

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.

See the rest here:
InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com - Defense World